Autolus Reports Q2 2025 Financial Results

Autolus Therapeutics ( (AUTL) ) has issued an update.

Autolus Therapeutics reported its financial results for Q2 2025, highlighting a net product revenue of $20.9 million from AUCATZYL®, which recently received conditional marketing authorization in the UK and EU. The company is advancing its clinical trials, with plans to initiate a Phase 2 trial in lupus nephritis and a Phase 1 trial in multiple sclerosis by the end of 2025. Despite a net loss of $47.9 million for the quarter, Autolus remains optimistic about its cash position and future growth opportunities, particularly with the promising data from the FELIX trial and the potential of obe-cel in treating autoimmune diseases.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Spark’s Take on AUTL Stock

According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.

The overall score reflects significant upward momentum in technical analysis, offset by financial challenges due to ongoing losses and cash flow issues. The positive earnings call outlook is tempered by valuation concerns given the negative P/E ratio.

To see Spark’s full report on AUTL stock, click here.

More about Autolus Therapeutics

Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies. The company operates in the biopharmaceutical industry, with a market focus on treatments for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) and autoimmune diseases.

Average Trading Volume: 1,981,490

Technical Sentiment Signal: Hold

Current Market Cap: $657.4M

See more insights into AUTL stock on TipRanks’ Stock Analysis page.